Pharmalittle: Compounders Sue FDA Over Diabetes Drug and Biogen's Telehealth Strategy
Tuesday, 8 October 2024, 07:03
Recent Pharmaceutical Trends
Pharmalittle discusses significant updates from the world of healthcare. A trade group representing major compounding pharmacies has filed a lawsuit against the FDA concerning its withdrawal of a popular diabetes and obesity drug from its shortages list.
Biogen's Innovative Approach
- Biogen is pivoting toward telehealth as a means to enhance patient access and care effectiveness.
- This strategy may reshape the future of pharmaceutical engagement with patients.
These developments not only reflect changes in regulatory landscapes but also the increasing integration of technology in healthcare. For further details, please consult the original source.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.